Loading...

Next Generation Orthopedic Technology Will Transform Global Care

Published
14 May 25
Updated
24 Sep 25
AnalystConsensusTarget's Fair Value
US$49.67
40.2% undervalued intrinsic discount
24 Sep
US$29.69
Loading
1Y
-26.2%
7D
-7.3%

Author's Valuation

US$49.6740.2% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on24 Sep 25
Fair value Decreased 4.85%

The modest decline in Enovis's future P/E and discount rate suggests slightly more conservative growth expectations and a lower required return, resulting in a decreased consensus price target from $52.20 to $49.67. What's in the News Enovis raised its full-year 2025 earnings guidance, now expecting revenue between $2.245 billion and $2.275 billion, above prior forecasts (Key Developments).

Shared on09 Aug 25
Fair value Decreased 7.28%

Enovis' price target has been revised lower, likely reflecting a modest decline in net profit margin despite slightly higher revenue growth expectations, resulting in a new consensus fair value of $53.40. What's in the News Enovis Corporation raised full-year 2025 revenue guidance to $2.245 billion–$2.275 billion, up from prior expectations of $2.220 billion–$2.250 billion.